- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1918
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib ; volume:42 ; number:3 ; day:23 ; month:2 ; year:2022 ; pages:221-235 ; date:3.2022
Clinical drug investigation ; 42, Heft 3 (23.2.2022), 221-235, 3.2022
- Urheber
-
Piscitelli, Joseph
Chen, Joseph
LaBadie, Robert R.
Salageanu, Joanne
Chung, Chin-Hee
Tan, Weiwei
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-022-01125-x
- URN
-
urn:nbn:de:101:1-2022060920322903795007
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Piscitelli, Joseph
- Chen, Joseph
- LaBadie, Robert R.
- Salageanu, Joanne
- Chung, Chin-Hee
- Tan, Weiwei
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian
Brigatinib pharmacokinetics in patients with chronic hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian
Brigatinib pharmacokinetics in patients with chronic hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian
Brigatinib pharmacokinetics in patients with chronic hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment